Catalog No.
DHF92414
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q02223 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific Antibody
Clone ID
REGN5458
An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma., PMID:40507995
CAR-T cell-associated neurotoxicity during therapy of hematologic malignancies: incidence, clinical features, predictive biomarkers and management measures., PMID:40500259
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy., PMID:40499177
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies., PMID:40497952
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma., PMID:40491928
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma., PMID:40491859
Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies., PMID:40485666
Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states., PMID:40482292
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease., PMID:40450406
From myth to bedside: a scoping review of the applications of the chimeric antigen receptor in rheumatology., PMID:40481370
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies., PMID:40471555
Optimization of a novel 2+2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy., PMID:40465538
Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial., PMID:40462189
Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma., PMID:40461939
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma., PMID:40447948
Identification of a CAR-Derived Clone by NGS-Based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma., PMID:40446088
The impact of inpatient medication administration technologies on nursing autonomy and practice: a meta-ethnographic synthesis of the qualitative literature., PMID:40434395
Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies., PMID:40425193
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review., PMID:40425184
Genetically engineered extracellular vesicles expressing decoy protein TACI provide a therapeutic effect in systemic lupus erythematosus mouse model., PMID:40425096
Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy., PMID:40425008
Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab., PMID:40421459
Teclistamab-Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma., PMID:40421450
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation., PMID:40389394
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial., PMID:40383818
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance., PMID:40382213
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma., PMID:40380297
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing., PMID:40375902
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody., PMID:40374810
BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions., PMID:40372999
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting., PMID:40361170
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells., PMID:40359480
[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)]., PMID:40355350
Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy., PMID:40353815
Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis., PMID:40352937
Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis., PMID:40348718
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium., PMID:40346049
BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects., PMID:40338452
Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma., PMID:40332715
Quantification of total sBCMA in human plasma by peptide-level immunocapture LC-MS/MS., PMID:40331169
Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell Therapy., PMID:40330632
FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model-Based Assessments., PMID:40319449
[Immunosubstitution of patients with refractory multiple myeloma treated with teclistamab, a bispecific antibody]., PMID:40318828
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma., PMID:40315372
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma., PMID:40312353
First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report., PMID:40308587
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland., PMID:40308262
The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy., PMID:40295321
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis., PMID:40280037
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma., PMID:40279508
For research use only. Not for human or drug use.
